Clinical trials are a fundamental step in the development of new therapies for
treating virtually every medical condition. At Synta Pharmaceuticals, our
clinical research is focused on innovative therapeutic options that can extend
or enhance the lives of patients in the areas of cancer and inflammatory
diseases. All of the drug candidates currently in development at Synta are
derived from our proprietary chemical compound library and reflect our
commitment to truly original research.
Synta places a high priority on sharing information and results regarding our
ongoing and completed clinical studies with the medical community. We have
registered all of our active, company-sponsored clinical trials on the National
Institutes of Health Web site
www.clinicaltrials.gov. This information is available here on our site,
as well.
No Synta drug candidates have been approved by the FDA or any other regulatory
body for the treatment of diseases.
Ganetespib
Ganetespib is a potent, second-generation, small molecule Hsp90 inhibitor
(inhibits heat shock protein 90 - Hsp90 a chaperone that regulates numerous
proteins that drive proliferation in cancer cells, in particular kinases) that
has shown strong activity in a broad range of preclinical solid and hematologic
cancer models, including models highly resistant to treatment. The chemical
structure of ganetespib is unrelated to the first generation, ansamycin family
of Hsp90 inhibitors (e.g., 17-AAG or IPI-504).
GALAXY Trial TM (Ganetespib Assessment in Lung
cAncer with docetaXel)
Phase 2b/3 Trial in Non-Small Cell Lung Cancer in Combination with Docetaxel
This is a randomized, Phase 2b/3 study of ganetespib (STA-9090) in combination
with docetaxel versus docetaxel alone being conducted in patients with stage
IIIb or IV non-small cell lung cancer (NSCLC). The primary objectives are to
measure change in progression free survival and overall survival. Click here for more information on this trial.
Phase 1 in Combination with Docetaxel in Solid Tumors
Results from this trial were announced in September
2011 and
at The European Multidisciplinary Cancer Congress.
Phase 2 Trial in Non-Small Cell Lung Cancer
Results from this trial were announced in June 2011 and
at ASCO 2011.
Phase 2 Trial in Colorectal Cancer
This is an open-label, investigator-sponsored Phase 2 clinical study being
conducted in patients with advanced colon cancer or rectal cancer.
Click here for more information on this trial.
Phase 2 Trial in Gastric Cancer
This is an open-label, investigator-sponsored Phase 2 clinical study being
conducted in patients with advanced gastric, esophageal, or gastroesophageal
cancers.
Click here for more information on this trial.
Phase 2 Trial in Ocular Melanoma
This is an open-label, investigator-sponsored Phase 2 clinical study being
conducted in patients with metastatic ocular melanoma. Click here for more information on this trial.
Phase 2 Trial in Pancreatic Cancer
This is an open-label, investigator-sponsored Phase 2 clinical study being
conducted in patients with metastatic pancreatic cancer. Click here for more information on this trial.
Phase 2 Trial in Prostate Cancer
This is an open-label, investigator-sponsored Phase 2 clinical study being
conducted in patients with metastatic hormone-resistant prostate cancer
previously treated with docetaxel-based chemotherapy. Click here for more information on this trial.
Phase 2 in Combination with Dutasteride in Prostate Cancer
This is an open-label, investigator-sponsored Phase 2 clinical study being
conducted in patients with castration-resistant prostate cancer (CRPC). Click here for more information on this trial.
Phase 2 Trial in Breast Cancer
This is an open-label, investigator-sponsored Phase 2 clinical study being
conducted in patients with metastatic breast cancer. Click here for more information on this trial.
Phase 2 Trial in Melanoma
This is an open-label, investigator-sponsored Phase 2 clinical study being
conducted in patients with unresectable stage III or stage IV melanoma who were
intolerant of or progressed on prior tyrosine kinase inhibitor (TKI) treatment.
[Top of page]
Elesclomol
Phase 2 in Combination with Paclitaxel in Ovarian Cancer
This is a Phase 2 single-arm, open-label study in patients with recurrent
ovarian cancer, fallopian tube cancer or primary peritoneal cancer who have
progressed on platinum-based therapy. Click here for more information on this trial.
Phase 1 Trial in Acute Myeloid Leukemia (AML)
This is a Phase 1 dose-escalation study of elesclomol sodium in patients with
relapsed or refractory acute myeloid leukemia (AML). The primary objectives of
study are to characterize safety, tolerability, and pharmacokinetics.
Additional objectives are to identify the phase 2 dose and characterize signs
of biologic and clinical activity. Click here for more information on this trial.
[Top of page]
|
